deltatrials
Completed PHASE1 NCT01859078

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Effect of Baricitinib on the Pharmacokinetics of Digoxin in Healthy Subjects

Sponsor: Eli Lilly and Company

Conditions Healthy Volunteers
Interventions Baricitinib Digoxin
Updated 9 times since 2017 Last updated: May 15, 2017 Started: May 31, 2013 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

Listed as NCT01859078, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Eli Lilly and Company, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Feb 2017 — Jun 2017 [monthly]

    Completed PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Leeds, United Kingdom